Sucrets Vapor Cherry Lozenge
NDC Package 63736-925-18
Package Information
Sucrets Vapor Cherry (dyclonine hydrochloride and menthol) lozenges is do not use more than directedadults and children 4 years of age and older: allow lozenge to dissolve slowly in mouth. This formulation utilizes a lozenge delivery system. Marketed by Insight Pharmaceuticals Llc, this product is identified by NDC 63736-925 and is authorized under FDA application M022.
Identification & Billing
- RxCUI: 1038943 - dyclonine HCl 3 MG / menthol 6 MG Oral Lozenge
- RxCUI: 1038943 - dyclonine hydrochloride 3 MG / menthol 6 MG Oral Lozenge
- RxCUI: 1038947 - Sucrets Complete 3 MG / 6 MG Oral Lozenge
- RxCUI: 1038947 - dyclonine hydrochloride 3 MG / menthol 6 MG Oral Lozenge [Sucrets Complete]
- RxCUI: 1038947 - Sucrets Complete (dyclonine hydrochloride 3 MG / menthol 6 MG) Oral Lozenge
Clinical Specifications
Regulatory & Marketing
Hierarchy Structure
- 63736 - Insight Pharmaceuticals Llc
- 63736-925 - Sucrets Vapor Cherry
- 63736-925-18 - 18 LOZENGE in 1 CANISTER
- 63736-925 - Sucrets Vapor Cherry
The NDC Directory contains ONLY information on final marketed drugs submitted to FDA electronically by labelers. A labeler might be a manufacturer, re-packager or re-labeler. The product information included in the NDC directory does not indicate that FDA has verified the information provided by the product labeler. Assigned NDC numbers are not in any way an indication of FDA approval of the product.
* Please review the full disclaimer at the bottom of this page.
Frequently Asked Questions
What is the distribution configuration for this product package?
The code 63736-925-18 identifies a specific commercial package of 18 lozenge in 1 canister of Sucrets Vapor Cherry, a human over the counter drug labeled by Insight Pharmaceuticals Llc. This lozenge is formulated for oral use and contains dyclonine hydrochloride; menthol as the active substance.
Is this product currently listed with the FDA?
Yes, this product is active and verified within the NDC Directory. It was introduced to the market by Insight Pharmaceuticals Llc on July 28, 2009. The current certification is valid through December 31, 2026.
How is this Insight Pharmaceuticals Llc product billed for insurance claims?
For medical billing and reimbursement, this package follows the 11-digit CMS format: 63736092518. The table below illustrates the segment conversion from the 10-digit labeler code to the 11-digit provider format.
11-Digit Code Conversion
Billing payers usually require a 5-4-2 segment configuration. Below is the conversion from the 10-digit package format to the 11-digit billing format:
Note: The zero is added to the Product segment to maintain the 5-4-2 structure.